Ardelyx, Inc. drew down $50.0 million of funding from the Term F Loan under its existing loan and security agreement with SLR Investment Corp. and other lenders. The funds are intended for general corporate purposes and to support strategic initiatives. The loan maturity date is July 1, 2030, with an interest rate of 4.55% plus the greater of the 1-month SOFR reference rate or 3.5%. Ardelyx, Inc. is a biotechnology company that develops and commercializes commercial-stage drugs for kidney and gastrointestinal diseases.